Comparative Pharmacology
Head-to-head clinical analysis: QVAR 80 versus QVAR REDIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QVAR 80 versus QVAR REDIHALER.
QVAR 80 vs QVAR REDIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a corticosteroid that exhibits anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, chemokines, and arachidonic acid metabolites. It also reduces edema and mucus production in the airways.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
80 mcg orally via oral inhalation twice daily (maximum 320 mcg twice daily)
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.9 hours after inhalation. This short half-life supports twice-daily dosing but does not fully reflect pulmonary residence time.
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Primarily hepatic metabolism, with metabolites excreted in feces (60-70%) and urine (30-40%). Less than 1% of unchanged drug is excreted in urine.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid